LabGenomics Co., Ltd. (KOSDAQ:084650)
South Korea · Delayed Price · Currency is KRW 1,293.00
+19.00 (1.49%)
Apr 3, 2026, 3:30 PM KST
LabGenomics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 88,161 | 85,898 | 71,076 | 144,573 | 202,289 |
Other Revenue | -0 | -0 | - | 199.59 | 117.98 |
| 88,161 | 85,898 | 71,076 | 144,773 | 202,407 | |
Revenue Growth (YoY) | 2.63% | 20.85% | -50.91% | -28.48% | 69.41% |
Cost of Revenue | 58,786 | 55,714 | 41,578 | 48,652 | 77,521 |
Gross Profit | 29,375 | 30,184 | 29,499 | 96,121 | 124,886 |
Selling, General & Admin | 35,381 | 38,374 | 28,636 | 25,996 | 18,518 |
Research & Development | 1,871 | 2,681 | 2,624 | 1,865 | 556.87 |
Amortization of Goodwill & Intangibles | 3,782 | 3,274 | 1,324 | 77.07 | 63.39 |
Other Operating Expenses | 563.69 | 659.23 | 634.68 | 591.29 | 361.38 |
Operating Expenses | 84,292 | 48,675 | 36,422 | 29,915 | 20,368 |
Operating Income | -54,917 | -18,491 | -6,923 | 66,206 | 104,518 |
Interest Expense | -5,730 | -5,508 | -4,953 | -573.97 | -208.03 |
Interest & Investment Income | 849.85 | 2,160 | 4,546 | 1,111 | 154.71 |
Earnings From Equity Investments | -127.05 | -636.06 | -1,969 | -72.11 | -46.37 |
Currency Exchange Gain (Loss) | 27.93 | 67.53 | 1,215 | 1,145 | 2,146 |
Other Non Operating Income (Expenses) | 7,711 | 1,721 | -1,474 | -448.52 | 90.13 |
EBT Excluding Unusual Items | -52,185 | -20,686 | -9,557 | 67,367 | 106,655 |
Gain (Loss) on Sale of Investments | -1,369 | 4,278 | 1,016 | -3,929 | 2,531 |
Gain (Loss) on Sale of Assets | -90.34 | -72.83 | 1,409 | -44.62 | 0.9 |
Asset Writedown | -6,615 | -9,471 | - | - | -55.2 |
Pretax Income | -60,259 | -25,952 | -7,133 | 63,393 | 109,132 |
Income Tax Expense | 4,116 | -2,260 | -1,842 | 15,467 | 25,277 |
Earnings From Continuing Operations | -64,375 | -23,691 | -5,291 | 47,926 | 83,855 |
Earnings From Discontinued Operations | - | -212.79 | 44.98 | - | - |
Net Income to Company | -64,375 | -23,904 | -5,246 | 47,926 | 83,855 |
Minority Interest in Earnings | - | 108.11 | 571.89 | 471.27 | - |
Net Income | -64,375 | -23,796 | -4,674 | 48,397 | 83,855 |
Net Income to Common | -64,375 | -23,796 | -4,674 | 48,397 | 83,855 |
Net Income Growth | - | - | - | -42.29% | 96.08% |
Shares Outstanding (Basic) | 74 | 74 | 74 | 68 | 68 |
Shares Outstanding (Diluted) | 74 | 74 | 74 | 68 | 68 |
Shares Change (YoY) | 0.47% | -0.46% | 9.63% | 0.20% | 2.61% |
EPS (Basic) | -867.00 | -322.00 | -62.96 | 714.67 | 1240.72 |
EPS (Diluted) | -867.00 | -322.00 | -62.96 | 714.50 | 1240.50 |
EPS Growth | - | - | - | -42.40% | 91.05% |
Free Cash Flow | -31,674 | -16,663 | -8,817 | 31,307 | 51,645 |
Free Cash Flow Per Share | -426.59 | -225.48 | -118.76 | 462.30 | 764.15 |
Gross Margin | 33.32% | 35.14% | 41.50% | 66.39% | 61.70% |
Operating Margin | -62.29% | -21.53% | -9.74% | 45.73% | 51.64% |
Profit Margin | -73.02% | -27.70% | -6.58% | 33.43% | 41.43% |
Free Cash Flow Margin | -35.93% | -19.40% | -12.40% | 21.63% | 25.52% |
EBITDA | -44,607 | -8,891 | -1,027 | 70,171 | 107,858 |
EBITDA Margin | -50.60% | -10.35% | -1.44% | 48.47% | 53.29% |
D&A For EBITDA | 10,311 | 9,599 | 5,896 | 3,965 | 3,340 |
EBIT | -54,917 | -18,491 | -6,923 | 66,206 | 104,518 |
EBIT Margin | -62.29% | -21.53% | -9.74% | 45.73% | 51.64% |
Effective Tax Rate | - | - | - | 24.40% | 23.16% |
Advertising Expenses | 106.94 | 194.43 | 58.85 | 100.91 | 74.86 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.